Program notes:

0:35 Cell-free DNA screening for cancer and diagnosis delays

1:35 Populations-based screening

2:35 24 different companies offer liquid biopsy

3:01 Can we prevent chronic back pain after acute back pain?

4:01 Impact score on chronic back pain

5:01 Real-world setting lacks impact

6:01 Primary care role

7:01 Individual should assess their own back pain

7:25 Resistance training and mortality

8:25 Most benefit with aerobic and resistance training

9:20 GLP1 and knee arthroplasty

10:20 Using a GLP1 reduced risk of knee arthroplasty

11:23 Can't imagine using them solely for this purpose

12:25 End

Program notes:

0:37 Prehospital resuscitation with whole blood

1:37 Compared with blood components

2:35 Easier to store 

3:19 Azithromycin in wheezing kids

4:19 Treated for five days

5:26 Name change from PCOS to PMOS

6:26 Consensus build

7:28 Improved accuracy of pathophysiology

8:30 Adjust policy, change international classification

9:15 Biomarkers to direct lung cancer screening

10:15 Participants from several countries

11:15 What are barriers to those with a smoking history

12:24 End

Program notes:

0:36 24 hour ambulatory blood pressure and exercise

1:36 Aerobic, combined and HIT helped

2:36 Some combined with other things known to be beneficial

2:54 Medium sized vessel thrombectomy

3:54 Thrombectomy or medical management

4:54 Carefully selected patients benefit

5:55 About fifty to sixty percent end up with minimal impact

6:40 Digoxin as fifth pillar of congestive heart failure management

7:40 Does help avoid hospitalization

8:37 Maternal occupation and autism in offspring

9:35 Jobs held ever, before conception and other periods

10:35 How to protect against exposure

11:30 Confine your employment?

12:13 End

Program notes:

0:40 Transcranial stimulation for ASD

1:40 Used evoked potential and quick pulses

2:41 Motor cortex associated with speech and language

3:27 A model for benefits from GLP-1 use

4:27 Discern who would be most likely to develop obesity complications

5:27 Target to those more likely to have comorbidity

6:10 GLP-1 and AUD

7:10 Followed for 26 weeks

8:10 Side effects when someone doesn't have obesity

8:30 Consultants and nonprofit hospitals

9:33 Matched with hospitals that did not use

10:33 No benefits related to consultants

11:31 Told you what they knew already

12:55 End

Program notes:

0:35 Factors regarding vaccine uptake

1:35 Adolescents didn't like human to human

2:35 Free vaccines helpful

3:00 Treating osteoarthritis of the knee

4:00 Dose response to reduce pain score

5:00 Does it elicit an immune response

5:35 Factors in increasing cancer rates in younger people

6:35 Things other than patient attributable factors

7:35 Unregulated growth with exposure

8:00 Treatment of uncomplicated UTIs in women

9:00 Symptoms plus dipstick

10:00 Short courses of antibiotics

11:01 Even single treatment disrupts

11:57 End

Program notes:

0:30 Controlling HTN after intracerebral hemorrhage

1:30 Triple pill or placebo

2:30 Only effective treatment is lowering blood pressure

3:32 Serum creatinine levels

4:15 Is there a role for Paxlovid?

5:15 Did not reduce hospitalization or death

6:10 Fast antimicrobial susceptibility test for gram negative

7:10 Desirability of outcome ranking or DOOR

8:10 Median time to effective therapy reduced

9:10 Was not superior

10:07 Acute sinusitis treatment

11:15 Secondary effects higher with augmentin

12:21 End

Program notes:

0:34 Chronotrope type and timing of exercise

1:36 Sedentary adults and morning or evening type

2:36 Acting as your own control

3:10 Stenting for post thrombotic syndrome

4:10 Severity lower with endovascular therapy

5:10 Patent in 2/3 at six months

6:10 Very diverse patient populations

6:28 Estimating kidney function

7:28 Currently underestimate compromise

8:27 Deprescribing proton pump inhibitors

9:27 Three different interventions

10:27 Almost 15% achieved outcome in both patient and physician

12:08 End

Program notes:

0:36 How low should cholesterol be targeted in secondary prevention?

1:40 33% reduction with target to 55

2:36 Able to do it with statin and other drugs

3:03 Deprescribing levothyroxine

4:06 Were able to discontinue in many

5:05 Thyroid not as responsive with aging

6:05 Barriers to deprescribing?

6:31 Treatment of HTN in low-income patients

7:31 75% unemployed

8:31 Patient participates

9:06 Manufacturer coupon use

10:10 Annual patient use of coupons

11:18 Used to drive people to use drugs that are expensive

12:33 End